• 1
    de Vries C, Veerman H, Pannekoek H. Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin. J Biol Chem 1989; 264: 1260410.
  • 2
    de Vries C, Veerman H, Koornneef E, Pannekoek H. Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin. J Biol Chem 1990; 265: 1354752.
  • 3
    Nesheim M, Walker J, Wang W, Boffa M, Horrevoets A, Bajzar L. Modulation of fibrin cofactor activity in plasminogen activation. Ann N Y Acad Sci 2001; 936: 24760.
  • 4
    Stewart RJ, Fredenburgh JC, Rischke JA, Bajzar L, Weitz JI. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. J Biol Chem 2000; 275: 3661220.
  • 5
    Nesheim M, Bajzar L. The discovery of TAFI. J Thromb Haemost 2005; 3: 213946.
  • 6
    Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994; 5: 53742.
  • 7
    CRASH-2 C. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096101.
  • 8
    Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93: 64754.
  • 9
    Anand S, Diamond SL. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction. Circulation 1996; 94: 76374.
  • 10
    Diamond SL. Systems biology to predict blood function. J Thromb Haemost 2009; 7(Suppl. 1): 17780.
  • 11
    Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007; 5: 80411.
  • 12
    Longstaff C, Thelwell C, Williams SC, Silva MM, Szabo L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117: 6618.
  • 13
    Longstaff C, Whitton CM. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. J Thromb Haemost 2004; 2: 141621.
  • 14
    Longstaff C, Merton RE, Sinniger V. A comparison of cultured cells with other promoters of tissue plasminogen activator kinetics. Fibrinolysis 1995; 9: 17887.
  • 15
    Daas A. CombiStats v4.0, EDQM – Council of Europe. EDQM, Council of Europe, 2008. Accessed April 2012.
  • 16
    R development core team. R: a Program for Statistical Computing.. Vienna, Austria: R Foundation for Statistical Computing, 2010.
  • 17
    Mendes P. GEPASI: a software package for modelling the dynamics, steady states and control of biochemical and other systems. Comput Appl Biosci 1993; 9: 56371.
  • 18
    Mendes P. Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. Trends Biochem Sci 1997; 22: 3613.
  • 19
    Horrevoets AJG, Pannekoek H, Nesheim ME. A steady-state template model that describes the kinetics of fibrin-stimulated [Glu1]- and [Lys78]plasminogen activation by native tissue-type plasminogen activator and variants that lack either finger or kringle-2 domain. J Biol Chem 1997; 272: 218391.
  • 20
    Marti DN, Hu CK, An SS, von Haller P, Schaller J, Llinas M. Ligand preferences of kringle 2 and homologous domains of human plasminogen: canvassing weak, intermediate, and high-affinity binding sites by 1H-NMR. Biochemistry 1997; 36: 11591604.
  • 21
    Sinniger V, Merton RE, Fabregas P, Felez J, Longstaff C. Regulation of tissue plasminogen activator activity by cells. Domains responsible for binding and mechanism of stimulation. J Biol Chem 1999; 274: 1241422.
  • 22
    Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 2010; 8: 86876.
  • 23
    Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2717681.
  • 24
    Miles LA, Andronicos NM, Felez J, Grella DK, Castellino FJ, Gong Y. The role of lys-plasminogen in cell-mediated plasmin production. In: Waisman DM, ed. Plasminogen: Structure, Activation and Regulation. New York: Kluwer Academic, 2003: 10319.
  • 25
    Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1: 20007.
  • 26
    Longstaff C, Williams S, Thelwell C. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem 2008; 6: 21223.
  • 27
    Colucci M, D’Aprile AM, Italia A, Gresele P, Morser J, Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85: 6616.
  • 28
    Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 41623.
  • 29
    Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 1447782.
  • 30
    Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha-antiplasmin cross-linking. Blood 2011; 117: 63714.
  • 31
    Mutch NJ, Koikkalainen JS, Fraser SR, Duthie KM, Griffin M, Mitchell J, Watson HG, Booth NA. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010; 8: 201724.